Adma Biologics Inc [ADMA] stock is trading at $17.97, up 4.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ADMA shares have gain 3.22% over the last week, with a monthly amount drifted -8.74%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Buy rating on October 13, 2022, and set its price target to $5. On November 11, 2021, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $5 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4.50 on November 09, 2021. Jefferies initiated its recommendation with a Buy and recommended $8 as its price target on June 04, 2019. H.C. Wainwright reiterated a Buy rating for this stock on April 15, 2019, and upped its price target to $13.
Adma Biologics Inc [ADMA] stock has fluctuated between $4.37 and $23.64 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Adma Biologics Inc [NASDAQ: ADMA] shares were valued at $17.97 at the most recent close of the market. An investor can expect a potential return of 0.17% based on the average ADMA price forecast.
Analyzing the ADMA fundamentals
Adma Biologics Inc [NASDAQ:ADMA] reported sales of 382.81M for the trailing twelve months, which represents a growth of 78.13%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at 0.3%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.38 and Total Capital is 0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.34 points at the first support level, and at 16.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.38, and for the 2nd resistance point, it is at 18.78.
Ratios To Look Out For
For context, Adma Biologics Inc’s Current Ratio is 7.09. Also, the Quick Ratio is 3.26, while the Cash Ratio stands at 1.93. Considering the valuation of this stock, the price to sales ratio is 11.10, the price to book ratio is 18.32 and price to earnings (TTM) ratio is 65.04.
Transactions by insiders
Recent insider trading involved Tade Brad L., CFO and Treasurer, that happened on Nov 22 ’24 when 15000.0 shares were sold. President and CEO, Grossman Adam S completed a deal on Nov 22 ’24 to sell 48967.0 shares. Meanwhile, Director and Officer Grossman Adam S bought 48967.0 shares on Nov 22 ’24.
